Summary:
Salix Pharmaceuticals, Inc. an affiliate of Bausch Health US, LLC (the Sponsor) is running a research study to see if an investigational drug, named Rifaximin SSD-40IR given twice daily will help to delay the first episode of overt hepatic encephalopathy (OHE) requiring hospitalization, in patients with liver cirrhosis and how safe it is to use in people.
Criteria:
At minimum: Participant has a diagnosis of liver cirrhosis with medically controlled ascites (more than 30 days)
Qualified Participants May Receive:
You will be paid $80 for in-clinic visits and $40 for telephone visits. You will be paid following each completed visit.